All Trials

A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.

ClinicalTrials.gov ID: NCT05107674

An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced solid tumors or lymphoma that are refractory to standard therapies, whose tumors overexpress TrkA or harbor an NTRK1 gene fusion, to receive oral VMD-928, a highly selective irreversible TrkA inhibitor that acts via allosteric dimerization and inactivation of the target. Key exclusions include significant comorbidities and impaired drug absorption.

ClinicalTrials.gov ID: NCT03556228

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Pembrolizumab in Patients With Select Advanced Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with selected advanced solid tumors—including NSCLC, renal cell carcinoma, melanoma, platinum-resistant ovarian cancer, nasopharyngeal carcinoma, and triple negative breast cancer—who have progressed after specific prior therapies, to evaluate the safety and dosing of KFA115 (a novel immunomodulatory small molecule, presumed to enhance anti-tumor immunity) as monotherapy and in combination with pembrolizumab. Exclusion criteria include significant cardiac, autoimmune, and interstitial lung diseases, as well as history of severe hypersensitivity to study drugs.

ClinicalTrials.gov ID: NCT05544929

A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic EGFR-mutant (exon 19 or 21) non-small cell lung cancer, either treatment-naive or previously treated with EGFR TKIs, to receive osimertinib plus MRX-2843, an investigational oral MERTK/FLT3 tyrosine kinase inhibitor. The study aims to assess safety and optimal dosing for the combination in both TKI-naive and TKI-resistant settings.

ClinicalTrials.gov ID: NCT04762199

A Phase 1, Open-Label, Dose Escalation and Expansion Study of Mavrostobart (PT199) Administered Alone in Adult Patients with Advanced Solid TuMORs, in CombiNation with a Checkpoint INhibitor TreatinG Wild-type Non-Small Cell Lung Cancer, or in Combination with ChemoTherapy for Metastatic or Advanced PAncreatic Ductal AdenocaRcinoma (MORNINGSTAR)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including NSCLC without actionable mutations and pancreatic ductal adenocarcinoma—to receive Mavrostobart (PT199), an investigational anti-CD73 antibody targeting adenosine-mediated immunosuppression, as monotherapy or in combination with PD-1 inhibitors and/or chemotherapy. Eligible patients must have measurable disease and ECOG 0-1.

ClinicalTrials.gov ID: NCT05431270

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with metastatic solid tumors (mainly gastric, non-small cell lung, triple-negative breast, and cervical cancers) expressing KK-LC-1 and positive for HLA-A*01:01, who have exhausted standard therapies, receive lymphodepleting chemotherapy followed by a single infusion of autologous T cells engineered to express a T cell receptor targeting the KK-LC-1 antigen, plus aldesleukin. This trial investigates the safety and dosing of this KK-LC-1-specific TCR-T cell therapy.

ClinicalTrials.gov ID: NCT05483491

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This study enrolls adults with advanced or metastatic solid tumors (including selected breast, gynecologic, and gastrointestinal cancers) who have progressed on or are ineligible for standard therapies, investigating INCB123667 (mechanism unknown) as monotherapy or in combination with agents such as palbociclib, ribociclib, fulvestrant, bevacizumab, olaparib, or paclitaxel. Patients must have good performance status (ECOG 0-1), and the trial includes tumor-specific expansion cohorts.

ClinicalTrials.gov ID: NCT05238922

First-in-Human Phase I Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic solid tumors (such as pancreatic, colorectal, and breast cancers) who have progressed after standard therapies, as well as adolescents (12–17 years) with solid tumors lacking standard options (excluding rhabdomyosarcoma), to receive oral metarrestin, a first-in-class small molecule that targets the perinucleolar compartment to disrupt ribosome biogenesis and inhibit metastasis.

ClinicalTrials.gov ID: NCT04222413

A Phase I Dose Escalation and Dose Expansion Study of AND019 in Patients With Estrogen Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative Advanced or Metastatic Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls postmenopausal women with advanced or metastatic ER-positive, HER2-negative breast cancer who have progressed on prior endocrine therapy and no more than one chemotherapy for advanced disease, to receive oral AND019, an investigational selective estrogen receptor degrader (SERD) targeting the estrogen receptor. The study focuses on evaluating the safety and early activity of AND019 as monotherapy.

ClinicalTrials.gov ID: NCT05187832

Ph 1/1b/2 Multicenter, Open-Label, FIH Dose Esc & Dose Exp Study to Assess Safety and Tolerability of Orally Administered PMD-026 as a Single Agent and in Combination in Patients With Metastatic or Locally Advanced (Inoperable) RSK2+ Breast Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with RSK2-positive, HR+/HER2- locally advanced or metastatic breast cancer who have progressed after CDK4/6 inhibitor plus endocrine therapy, testing the investigational oral RSK inhibitor PMD-026 (which targets all four RSK isoforms in the MAPK/PDK-1 pathway) as monotherapy and in combination with fulvestrant. Eligible patients must provide tumor tissue for RSK2 analysis and have measurable disease.

ClinicalTrials.gov ID: NCT04115306